Daclacee
Generic Name
Daclatasvir 60 mg tablet
Manufacturer
Beacon Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| daclacee 60 mg tablet | ৳ 400.00 | ৳ 4,000.00 |
Description
Overview of the medicine
Daclatasvir is a direct-acting antiviral medication used in combination with other drugs to treat chronic hepatitis C virus (HCV) infection. It targets the NS5A protein, which is essential for HCV replication.
Uses & Indications
Dosage
Adults
60 mg orally once daily, in combination with other agents (e.g., Sofosbuvir). Duration typically 12 or 24 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience.
Elderly
No specific dose adjustment is generally needed for elderly patients.
Renal_impairment
No dose adjustment is needed for patients with any degree of renal impairment, including those on dialysis.
How to Take
Oral administration. Can be taken with or without food. Should be taken at the same time each day.
Mechanism of Action
Daclatasvir inhibits the hepatitis C virus (HCV) nonstructural protein 5A (NS5A), a phosphoprotein that plays a critical role in HCV replication, including viral RNA replication and virion assembly.
Pharmacokinetics
Onset
Not an acute onset drug; viral load reduction begins within days of starting treatment.
Excretion
Primarily via feces (approx. 88%), with a smaller amount in urine (approx. 6.6%).
Half life
Approximately 12-15 hours.
Absorption
Rapidly absorbed, peak plasma concentration typically 2 hours post-dose. Bioavailability around 67%.
Metabolism
Primarily metabolized by cytochrome P450 3A4 (CYP3A4).
Side Effects
Contraindications
- •Hypersensitivity to daclatasvir or any component of the formulation.
- •Co-administration with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine, St. John's wort) due to potential for loss of efficacy.
Drug Interactions
Amiodarone
Co-administration with sofosbuvir and another direct-acting antiviral, including daclatasvir, may lead to symptomatic bradycardia; co-administration is not recommended.
Ketoconazole, Clarithromycin, Ritonavir
Strong CYP3A inhibitors, co-administration may increase daclatasvir plasma concentrations, requiring dose reduction in some cases.
Rifampin, Phenytoin, Carbamazepine, St. John's wort
Strong CYP3A inducers, co-administration is contraindicated due to decreased daclatasvir plasma concentrations and potential for loss of virologic response.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Limited experience with overdose. In cases of overdose, treatment should be symptomatic and supportive. Daclatasvir cannot be efficiently removed by hemodialysis.
Pregnancy & Lactation
Pregnancy Category B. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown if daclatasvir is excreted in human milk; advise women not to breastfeed during treatment.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 to 36 months from the date of manufacture, depending on storage conditions.
Availability
Pharmacies, hospitals
Approval Status
FDA approved
Patent Status
Patent expired in many countries; generic versions available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in